Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Therapeutic Hepatitis C Virus Antibodies

Posted Feb 04 2013 7:00pm

Description of Invention:
Therapeutic antibodies against Hepatitis C Virus (HCV) have not been very effective in the past and there is evidence that this may result in part from interfering antibodies generated during infection that block the action of neutralizing antibodies. These neutralizing antibodies prevent HCV infection of a host cell.

The subject technologies are monoclonal antibodies against HCV that can neutralize different genotypes of HCV. Both antibodies bind to the envelope (E2) protein of HCV found on the surface of the virus. One of the monoclonal antibodies neutralizes HCV genotype 1a, the most prevalent HCV strain in the U.S., infection and in vitro data show that it is not blocked by interfering antibodies. The second antibody binds a conserved region of E2 and can cross neutralize a number of genotypes including genotypes 1a and 2a. The monoclonal antibodies have the potential to be developed either alone or in combination into therapeutic antibodies that prevent or treat HCV infection. These antibodies may be particularly suited for preventing HCV re-infection in HCV patients who undergo liver transplants; a population of patients that is especially vulnerable to the side effects of current treatments for HCV infection.

Applications:
Therapeutic antibodies for the prevention and/or treatment of HCV infection.

Advantages:
  • Therapeutic antibodies have generally fewer side effects than current treatments for HCV infection.
  • Potential to be developed into an alternative treatment for HCV infected liver transplant patients, who often cannot tolerate the side effects of current drug treatments.


Development Status:
  • Early-stage
  • Pre-clinical
  • In vitro data available


Inventors:
Stephen M Feinstone (FDA)
Hongying Duan (FDA)
Marian E Major (FDA)
Pei Zhang (FDA)
Alla V Kachko (FDA)


Patent Status:
HHS, Reference No. E-002-2012/0
US, Application No. 61/648,386 filed 17 May 2012
PCT, Application No. PCT/US12/62197 filed 26 Oct 2012


Relevant Publication:
  1. Kachko A, et al. [ PMID 22041300 ]
  2. Duan H, et al. [ PMID 22973024 ]



For Licensing Information Please Contact:
Kevin Chang Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: changke@mail.nih.gov
Phone: 301-435-5018
Fax: 301-402-0220


Ref No: 2524

Updated: 02/2013

Post a comment
Write a comment:

Related Searches